Angiotensin Receptor Antagonists Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis

MARKET INTRODUCTION

Angiotensin receptor blockers (ARBs) or angiotensin II receptor antagonists, are used to treat cardiac conditions like high blood pressure, heart attack and heart failure. They are also prescribed for chronic kidney disease. Valsartan, losartan and candesartan are examples of angiotensin receptor antagonists.

MARKET DYNAMICS

The angiotensin receptor antagonists market is expected to grow owing to growing prevalence of cardiac conditions and increasing incidence of chronic kidney disease. Moreover, growing pharmaceutical industry across the globe may create growth opportunities for the market.

MARKET SCOPE

The "Angiotensin Receptor Antagonists Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of angiotensin receptor antagonists market with detailed market segmentation by type, and application. The angiotensin receptor antagonists market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in angiotensin receptor antagonists market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The angiotensin receptor antagonists market is segmented on the basis of type, and application. Based on type, the market is segmented as valsartan, telmisartan, losartan, irbesartan, azilsartan, and olmesartan. The application segment is categorized into hypertension, cardiovascular diseases, kidney diseases, and other.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the angiotensin receptor antagonists market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The angiotensin receptor antagonists market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting angiotensin receptor antagonists market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Angiotensin receptor antagonists market in these regions.

MARKET PLAYERS

The report covers key developments in the angiotensin receptor antagonists market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from angiotensin receptor antagonists market are anticipated to have lucrative growth opportunities in the future with the rising demand for angiotensin receptor antagonists in the global market. Below mentioned is the list of few companies engaged in the angiotensin receptor antagonists market.

The report also includes the profiles of key players in angiotensin receptor antagonists market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

•   Pfizer
  
•   Novartis
  
•   Merck
  
•   Astra Zeneca
  
•   Johnson and Johnson
  6. Eli Lilly
  7. Sanofi
  
•   Bristol-Myers Squibb
  
•   Bayer
  
•   GSK
  

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.

Angiotensin Receptor Antagonists Report Scope